Tizos
Indonesia • Dexa Medica
Indication
The following infections caused by ceftizoxime susceptible Streptococcus sp. (excluding Enterococci), Streptococcus pneumoniae, Haemophilus influenzae, Escherichia coli, Klebsiella sp., Proteus sp., Serratia sp., Enterobacter sp., Citrobacter sp., Peptococcus sp., Peptostreptococcus sp., and Bacteroides sp.
Composition
Ceftizoxime 1.000 mg
Package
Dosage Forms
Powder for InjectionATC Classification
Warning
Dosage
6 Months to 18 Years Old
Intravenous injection:
For children 6 months or older usually 40-80 mg/kg/day of ceftizoxime in 2-4 equally divided doses, increased to 120 mg/kg/day for severe or intractable infections, according to the age and condition of the patient.
18 Years Old and Above
Intravenous injection:
Usually 0.5-2 g/day of ceftizoxime is administered intravenously in 2-4 equally divided doses, increased to 4 g/day for severe or intractable infections, according to the age and condition of the patient.
Intramuscular injection:
Usually 0.5-2 g/day of ceftizoxime is administered intramuscularly in 2-4 equally divided doses, according to the age and condition of the patient.